Effect of Shugan Jieyu capsule on depression in patients with schizophrenia / 中国基层医药

ABSTRACT

Objective@#To investigate the effect of Shugan Jiayu capsule on depression in patients with schizophrenia.@*Methods@#From January 28, 2016 to January 24, 2017, 82 schizophrenic patients in Wenling Psychiatric Rehabilitation Hospital were selected in the study.All the patients had depressive symptoms and were divided into two groups by random number table method, with 41 cases in each group.Both two groups were treated with routine therapy.The control group was treated with quetiapine, and the observation group was given Shugan Jieyu capsule.The improvement of the disease and the occurrence of adverse events in the two groups were observed.@*Results@#At two weeks and one month after treatment, the Hamilton Depression Scale(HAMD) scores of the observation group[(16.97±2.23)points and (12.53±1.88)points] were lower than those of the control group (t=3.06, 5.52, all P<0.05). After one week, two weeks and one month of treatment, the Brief Psychiatric Rating Scale(BPRS) scores of the observation group[(30.29±2.41)points, (25.47±2.59) and (21.03±2.77)points] were lower than those of the control group (t=6.17, 6.60, 10.20, all P<0.05). After one week, two weeks and one month of treatment, the Positive and Negative Symptom Scale(PANSS) scores of the observation group were (72.76±3.83)points, (41.50±3.46)points and (33.94±2.89)points, respectively, which were better than those of the control group(t=4.02, 12.25, 13.40, all P<0.05). The incidence rate of adverse events in the observation group[4.88%(2/41)] was obviously lower than that in the control group[19.51%(8/41)](χ2=4.10, P<0.05). The recurrence rates of the observation group after 3 months and 6 months were 7.32%(3/41) and 12.20%(5/41), respectively, which were lower than those of the control group[26.83%(11/41) and 34.15%(14/41)](χ2=5.51, 5.55, P<0.05).@*Conclusion@#Shugan Jieyu capsule can effectively improve the depressive symptoms of schizophrenia patients.